MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis

Hirschsprung Disease Clinical Trial

— MICROPRUNG  

Official title:

MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02857205
• Other study ID #: 35RC15_9873_MICROPRUNG
• Secondary ID: 2015-A01317-42
• Status: Completed
• Phase: N/A
• Start date: June 2016
• Est. completion date: September 2018

Study information

• Verified date: September 2018
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hirschsprung disease is a congenital abnormality due to the lack of migration of neural crest cells in myenteric and submucosal plexi of the bowel wall. The consequence is the absence of parasympathetic control of the distal bowel from the anal sphincter to various levels. The most common type of Hirschsprung disease alters the rectosigmoid (80%). The incidence is around 1/5000 live births. This anomaly requires a surgical ablation of the aganglionic segment.

Regardless of the surgical complications, patients with Hirschsprung disease are exposed to the risk of Hirschsprung Associated EnteroColitis (HAEC). This variable risk, 4-54%, is responsible to a major part of Hirschsprung disease morbimortality. Its onset is more frequent during the first two years of life and then decrease with age.

Its pathogenesis remains unclear but could be due to intestinal homeostasis breakdown that involves microbiota, intestinal barrier, immune system and enteric nervous system. This breakdown of the mutual benefit relation due to microbiota or bowel anomaly is known to be responsible of Crohn's disease onset. Some studies emphasize the role of microbiota in the pathogenesis of HAEC, but the techniques or the methodology with small numbers of patients limit any conclusion or clinical use.

The study hypothesizes microbiota is a major factor in HAEC onset and in their functional bowel problems. Considering HAEC is more frequent the first two years, it's thought that intestinal microbiota changes with time in those patients. This project is innovative because it will use high throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Multicentre transversal study.

This study has the potential to significantly modify clinical practice for Hirschsprung disease patients: a better care for HAEC and functional troubles thanks to a better understanding of their microbiota, targetted antibiotic treatment for HAEC, prophylactic treatment of patients at high risk of HAEC.

Description:

Primary objective :

Characterize intestinal microbiota in patients with or without HAEC.

Secondary objectives :

• Look for a difference in microbiota composition between patients with or without HAEC ;

• Study the evolution with age of the microbiota in Hirschsprung disease patients ;

• Study predominant taxonomic classification elements in both groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 118
• Est. completion date: September 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 16 Years

Eligibility

Inclusion Criteria:

• Patients from 0 to 16 years ;

• With rectosigmoid Hirschsprung's disease confirmed by rectal biopsies and at surgery;

• Already operated on, whatever the surgical technique was ;

• With a health care insurance;

• Clear information and signed consent form

Exclusion Criteria:

• Long segment Hirschsprung disease ;

• Syndromic Hirschsprung disease ;

• Down syndrome.

Related Conditions & MeSH terms

• Enterocolitis
• Hirschsprung Disease

Intervention

Other:
• Fecal samples
High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Locations

Country	Name	City	State
France	Angers University Hospital	Angers
France	Brest University Hospital	Brest
France	Caen Univeristy Hospital	Caen
France	Nantes University Hospital	Nantes
France	Poitiers University Hospital	Poitiers
France	Rennes University Hospital	Rennes
France	Tours University Hospital	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intestinal microbiota composition	Characterize intestinal microbiota in patients with or without HAEC	Sampling day